Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2014
Business Overview: Matinas is a development-stage biopharmaceutical company focused on treating dyslipidemia and cardiovascular/metabolic diseases. The company has no commercial revenue and is primarily developing its lead product candidate, MAT9001 (an omega-3 fatty acid composition for severe hypertriglyceridemia), and a discovery program, MAT8800, for liver diseases. The company is classified as a "smaller reporting company" and an "emerging growth company."
Key Financial Metrics
| Metric | Q1 2014 | Q1 2013 | Inception to Q1 2014 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2,139,024) | $(112,133) | $(5,969,742) |
| Net Loss Per Share (Basic/Diluted) | $(0.07) | $(0.01) | N/A |
| Cash and Cash Equivalents (End of Period) | $8,558,105 | $659,676 | N/A |
| Net Cash Used in Operating Activities | $(2,089,046) | $(150,123) | $(5,134,144) |
| Total Assets | $9,326,576 | N/A | N/A |
| Total Liabilities | $716,986 | N/A | N/A |
| Accumulated Deficit | $(5,969,742) | N/A | N/A |
Debt and Liquidity: The company has no long-term debt. Total liabilities consist primarily of accounts payable, accrued expenses, and lease liabilities. As of March 31, 2014, the company held approximately $8.6 million in cash, which management estimates is sufficient to fund operations until approximately January 2015.
Material Changes vs. Prior Period
- Operating Expenses: Total costs and expenses increased significantly from $112,133 in Q1 2013 to $2,129,027 in Q1 2014.
- Research and Development (R&D): Increased from $49,586 to $1,073,781, driven by manufacturing process development, preclinical studies, and regulatory activities for MAT9001.
- General and Administrative (G&A): Increased from $62,547 to $1,055,247, primarily due to increased personnel compensation, legal fees related to the registration statement, and compliance costs associated with being a public company.
- Cash Position: Cash and cash equivalents decreased by approximately $2.3 million during the quarter due to operating losses and capital expenditures for laboratory equipment ($193,277).
- Stock-Based Compensation: Recognized $273,824 in stock-based compensation expense in Q1 2014, compared to $0 in Q1 2013.
Guidance, Outlook, and Risks
Outlook and Guidance:
- The company expects to continue incurring substantial losses for the foreseeable future.
- Management anticipates filing an Investigational New Drug (IND) application with the FDA in mid-2014 and commencing human studies shortly thereafter.
- Phase III pivotal studies for MAT9001 are expected to commence in late 2014, with a New Drug Application (NDA) submission targeted for late 2016 and potential commercialization in 2017.
- Additional capital of at least $20 million to $60 million will be required to complete the Phase III program and submit an NDA if the FDA does not accept the proposed streamlined regulatory pathway.
Material Risks and Contingencies:
- Going Concern: Recurring losses and the need for additional funding raise substantial doubt about the company's ability to continue as a going concern. The independent auditor included an explanatory paragraph regarding this uncertainty in the 2013 audit report.
- Regulatory Approval: Success depends entirely on obtaining FDA approval for MAT9001. There is no guarantee that clinical trials will be successful or that the FDA will accept the proposed regulatory pathway.
- Internal Controls: The company identified material weaknesses in internal control over financial reporting related to financial closing procedures, lack of resources for equity transactions, and segregation of duties. Remediation efforts are underway but not yet complete.
- Competition: The company faces competition from established products (e.g., Lovaza, Vascepa) and generic versions entering the market.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the projection that current cash ($8.6M) will sustain operations only until January 2015.
- Capital Requirements: Assess the feasibility of raising the estimated $20M–$60M needed for Phase III trials and NDA submission.
- Regulatory Pathway: Monitor FDA communications regarding the acceptance of the proposed Section 505(b)(2) regulatory pathway for MAT9001.
- Internal Controls: Review future filings for confirmation that material weaknesses in internal controls have been remediated.
- Dilution Risk: Note the existence of 15,250,000 outstanding warrants and 3,160,000 stock options, which could significantly dilute existing shareholders upon exercise.